in vitro News and Research

RSS

Kolltan announces presentation of data from KTN0158 preclinical study in mast cell tumors at ESMO 2015

Kolltan Pharmaceuticals, Inc. today announced the presentation of data from a preclinical study evaluating KTN0158 in dogs with spontaneous mast cell tumors. KTN0158 is a proprietary, humanized anti-KIT IgG1 monoclonal antibody drug candidate being developed as a potential therapy for cancer and mast cell-related diseases.

28 Sep 2015

Standard clomiphene treatment better than proposed alternative for unexplained fertility

It is estimated that approximately 10 percent of women of child-bearing age may be unable to get pregnant or to carry a pregnancy to term.

26 Sep 2015

New study on deep-diving whales may help researchers create synthetic blood for human trauma patients

The ultra-stable properties of the proteins that allow deep-diving whales to remain active while holding their breath for up to two hours could help Rice University biochemist John Olson and his colleagues finish a 20-year quest to create lifesaving synthetic blood for human trauma patients.

26 Sep 2015

HIV cure research may shift from single-therapy development model to combination therapy trials

The next five years of HIV research should shift gears from the classic single-therapy development model to moving directly from in vitro studies to combination therapy trials, authors argue in a new paper published online today.

25 Sep 2015

EKF’s new Altair 240 revealed to UK audience at IBMS 2015

EKF, announces the UK launch of the Altair™ 240 clinical chemistry analyser at the Institute of Biomedical Science Congress 2015 in Birmingham.

From EKF Diagnostics 24 Sep 2015

Protein-coding gene identified as tumor suppressor for acute myeloid leukemia

A protein-coding gene called hnRNP K has been identified as a tumor suppressor for acute myeloid leukemia (AML), a finding that could be important for investigating how best to target treatment of a blood cancer striking mostly older individuals.

24 Sep 2015

Pabetalone (RVX-208) to be tested in proof-of-concept pilot study in complement mediated diseases

Resverlogix Corp. announced today the commencement of an Orphan Disease Program specific for Complement Mediated Diseases. New data generated by Resverlogix has demonstrated that BET inhibition by apabetalone (RVX-208) has effects on multiple biological pathways that underlie disease pathology.

24 Sep 2015

Novel mechanism may help explain the virulence of 1918 'Spanish' flu

While yearly outbreaks of flu kill about 250,000 to 500,000 people worldwide, the 1918 "Spanish" flu infected one-third of the world's population and killed 50 million to 100 million. Chad Petit, Ph.D., assistant professor in the University of Alabama at Birmingham Department of Biochemistry and Molecular Genetics, has discovered a novel mechanism for one 1918 flu virus protein that may help explain the virulence of that unusually deadly pandemic.

23 Sep 2015

Paxman unveils commitment to ‘chase zero hair loss during chemotherapy’ at 2015 European Cancer Congress

UK based Paxman – pioneers in scalp cooling – is unveiling their commitment to ‘chase zero hair loss during chemotherapy’ at the 2015 European Cancer Congress, Europe’s largest cancer platform being held in Vienna, Austria (September 25 – 29th, 2015).

From Paxman 23 Sep 2015

Study demonstrates potential of FCPCs as new source for cartilage regeneration

The self-repair of injured cartilage is difficult for several reasons, foremost of which is the lack of blood supply to the tissue. Therapeutic efforts aimed at cartilage repair are often not optimal. Surgical repair techniques often lead to the formation of fibrocartilage, which is weaker and less durable. Although cell transplantation aimed at cartilage repair has been carried out using mesenchymal stem cells (MSCs), varying outcomes have resulted, despite the propensity of MSCs to proliferate and differentiate.

23 Sep 2015

Researchers receive $13 million NIH grant to develop new stem cell-based assays for studying autism

The National Institutes of Health has awarded a $13 million grant over five years to develop and disseminate new stem cell-based technologies and assays for studying autism spectrum disorder (ASD) and other mental health diseases to a consortium of researchers at the University of California, San Diego and the Salk Institute for Biological Studies, working in tandem with leaders in the biotechnology sector.

23 Sep 2015

VolitionRx's NuQ blood test receives CE Mark approval for detection of colorectal cancer

VolitionRx Limited today announced the Company's first CE Mark for its blood-based diagnostic assay, NuQ X001S, for detection of colorectal cancer. The NuQ test utilizes the Company's proprietary Nucleosomics technology platform, which identifies and analyses fragments of chromosomes, called nucleosomes, circulating within the blood for the presence of epigenetic cancer signals.

22 Sep 2015

$Common Alzheimer's disease drug increases bone density, reduces fracture risks$

Common Alzheimer's disease drug increases bone density, reduces fracture risks

The most common drug used to treat Alzheimer's disease increases bone mass in mice, according to one of the first research articles published in the new open access journal Heliyon. The authors of the study, from Saitama Medical University in Japan, say this means the drug could also be used to treat bone loss diseases like osteoporosis and periodontitis, following further clinical research.

21 Sep 2015

New Locilex microbiology data presented at ICAAC/ICC 2015 scientific conference

Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), and research collaborators, JMI Laboratories, announced that new Locilex microbiology data were presented at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy's International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific conference in San Diego, California, September 17-21, 2015.

21 Sep 2015

Promising new innovations in drug development, health monitoring may improve drug safety in the future

Adverse drug reactions are harmful to patients and a major burden for healthcare providers, governments and the pharmaceutical industry. But promising new breakthroughs in drug development and health monitoring may enhance drug safety in the future, according to an editorial to be published in the next edition of the British Journal of Clinical Pharmacology.

21 Sep 2015

Combination of TXA709 and cefdinir demonstrates synergistic antibacterial activity against MRSA

TAXIS Pharmaceuticals, a drug-discovery company focused on developing a new class of antibiotic agents to treat life-threatening, multidrug-resistant bacterial infections, announced the presentation of results demonstrating the synergistic antibacterial activity of its lead clinical candidate, TXA709, when combined with cefdinir, a third-generation cephalosporin antibiotic.

19 Sep 2015

Researchers identify new epigenetic markers for colorectal cancer

Researchers at Nanjing University, China, found new epigenetic markers for colorectal cancer which may offer a new approach for treatment.

14 Sep 2015

Scientists discover mechanism that could lead to new treatment for allergies

Most people with allergies have to take medication throughout their life: Their body "thinks" that proteins from the environment are so "strange" that they elicit an immune reaction. Until present, it was not possible to develop an efficient therapy so that the body "learns" to stop in an overreacting way.

8 Sep 2015

New study reveals pivotal role of miR-506 biomarker in gastric cancer

Gastric cancer poses a significant health problem in developing countries and is typically associated with late-stage diagnosis and high mortality. A new study in The American Journal of Pathology points to a pivotal role played by the biomarker microRNA (miR)-506 in gastric cancer.

8 Sep 2015

Penn researchers identify viral products that trigger immune response against RSV infection

Almost all human beings are exposed to the respiratory syncytial virus, or RSV, before their second birthdays. For most, the symptoms mimic those of the common cold: runny nose, coughing, sneezing, fever.

4 Sep 2015

in vitro News and Research

Kolltan announces presentation of data from KTN0158 preclinical study in mast cell tumors at ESMO 2015

Standard clomiphene treatment better than proposed alternative for unexplained fertility

New study on deep-diving whales may help researchers create synthetic blood for human trauma patients

HIV cure research may shift from single-therapy development model to combination therapy trials

EKF’s new Altair 240 revealed to UK audience at IBMS 2015

Protein-coding gene identified as tumor suppressor for acute myeloid leukemia

Pabetalone (RVX-208) to be tested in proof-of-concept pilot study in complement mediated diseases

Novel mechanism may help explain the virulence of 1918 'Spanish' flu

Paxman unveils commitment to ‘chase zero hair loss during chemotherapy’ at 2015 European Cancer Congress

Study demonstrates potential of FCPCs as new source for cartilage regeneration

Researchers receive $13 million NIH grant to develop new stem cell-based assays for studying autism

VolitionRx's NuQ blood test receives CE Mark approval for detection of colorectal cancer

Common Alzheimer's disease drug increases bone density, reduces fracture risks

New Locilex microbiology data presented at ICAAC/ICC 2015 scientific conference

Promising new innovations in drug development, health monitoring may improve drug safety in the future

Combination of TXA709 and cefdinir demonstrates synergistic antibacterial activity against MRSA

Researchers identify new epigenetic markers for colorectal cancer

Scientists discover mechanism that could lead to new treatment for allergies

New study reveals pivotal role of miR-506 biomarker in gastric cancer

Penn researchers identify viral products that trigger immune response against RSV infection

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News